VINCRISTINE, IRINOTECAN AND TEMOZOLOMIDE TREATMENT FOR RECURRENT/PROGRESSIVE PEDIATRIC SOLID TUMORS

被引：0
|
作者：
Kebudi, R. [1 ]
Bay, S. Buyukkapu [1 ]
Cakir, F. B. [2 ]
Gorgun, O. [1 ]
Koc, B. [1 ]
Zulfikar, B. [1 ]
Agaoglu, F. Yaman [3 ]
Darendeliler, E. [3 ]
机构：
[1] Istanbul Univ, Cerrahpasa Med Fac, Pediat Hematol Oncol, Istanbul, Turkey
[2] Bezmialem Vakif Univ, Fac Med, Pediat Hematol Oncol, Istanbul, Turkey
[3] Istanbul Univ, Inst Oncol, Radiat Oncol, Istanbul, Turkey
来源：
PEDIATRIC BLOOD & CANCER | 2015年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O-053
引用
收藏
页码：S158 / S159
页数：2
相关论文
共 50 条
  • [1] Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience
    Bay, Sema Bueyukkapu
    Kebudi, Rejin
    Gorgun, Omer
    Zulfikar, Buelent
    Darendeliler, Emin
    Cakir, Fatma B.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (06) : 1343 - 1348
  • [2] Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors
    Wagner, Lars
    Turpin, Brian
    Nagarajan, Rajaram
    Weiss, Brian
    Cripe, Timothy
    Geller, James
    PEDIATRIC BLOOD & CANCER, 2013, 60 (09) : 1447 - 1451
  • [3] A Phase I Study of Vincristine, Irinotecan, Temozolomide and Bevacizumab (Vitb) in Pediatric Patients with Relapsed Solid Tumors
    Venkatramani, Rajkumar
    Malogolowkin, Marcio
    Davidson, Tom B.
    May, William
    Sposto, Richard
    Mascarenhas, Leo
    PLOS ONE, 2013, 8 (07):
  • [4] Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors
    Hernandez-Marques, C.
    Lassaletta-Atienza, A.
    Ruiz Hernandez, A.
    Blumenfeld Olivares, J. A.
    Arce Abaitua, B.
    Cormenzana Carpio, M.
    Madero Lopez, L.
    ANALES DE PEDIATRIA, 2013, 79 (02): : 68 - 74
  • [5] Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors
    Kimura, T.
    Kashiwase, S.
    Makimoto, A.
    Kumagai, M.
    Taga, T.
    Ishida, Y.
    Ida, K.
    Nagatoshi, Y.
    Mugishima, H.
    Kaneko, M.
    Barrett, J. S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2010, 48 (05) : 327 - 334
  • [6] Phase 1 Study of Regorafenib in Combination With Vincristine and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
    Casanova, M.
    Bautista, F.
    Campbell-Hewson, Q.
    Makin, G.
    Marshall, L. V.
    Verschuur, A.
    Canete Nieto, A.
    Corradini, N.
    Ploeger, B.
    Mueller, U.
    Zebger-Gong, H.
    Chung, J.
    Geoerger, B.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S20 - S20
  • [7] An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors
    Tsakatikas, Sergios
    Papageorgiou, George
    Fioretzaki, Rodanthi
    Kosmas, Christos
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 166
  • [8] Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors.
    Casanova, Michela
    Bautista, Francisco
    Hewson, Quentin Campbell
    Makin, Guy
    Marshall, Lynley V.
    Verschuur, Arnauld
    Canete, Adela
    Corradini, Nadege
    Ploeger, Bart
    Mueller, Udo
    Zebger-Gong, Hong
    Chung, John Woojune
    Geoerger, Birgit
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Topotecan and Irinotecan in the Treatment of Pediatric Solid Tumors
    Tsuchida, Yoshiaki
    Shitara, Toshiji
    CURRENT PEDIATRIC REVIEWS, 2005, 1 (01) : 55 - 61
  • [10] Extended Phase I Evaluation of Vincristine, Irinotecan, Temozolomide, and Antibiotic in Children With Refractory Solid Tumors
    McNall-Knapp, Rene Y.
    Williams, Cydni N.
    Reeves, Elaine N.
    Heideman, Richard L.
    Meyer, William H.
    PEDIATRIC BLOOD & CANCER, 2010, 54 (07) : 909 - 915
12345